+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Basal Cell Carcinoma Drug"

From
From
From
From
From
Gorlin Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Gorlin Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 166 Pages
  • Global
From
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2020 - Product Thumbnail Image

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 487 Pages
  • Global
From
Gorlin Syndrome (Oncology) - Drugs In Development, 2021 - Product Thumbnail Image

Gorlin Syndrome (Oncology) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 186 Pages
  • Global
From
Loading Indicator

Basal Cell Carcinoma (BCC) is a type of skin cancer that is caused by exposure to ultraviolet radiation from the sun or tanning beds. BCC is the most common type of skin cancer, and is usually found on areas of the body that are exposed to the sun, such as the face, neck, and arms. Treatment for BCC typically involves topical medications, surgery, radiation therapy, or a combination of these treatments. The BCC drug market is composed of a variety of medications used to treat the disease. These medications include topical creams, gels, and ointments, as well as oral medications. Topical medications are typically used to treat superficial BCC, while oral medications are used to treat more advanced cases. Radiation therapy is also used to treat BCC, and is often used in combination with other treatments. The BCC drug market is highly competitive, with a number of companies offering products for the treatment of BCC. Some of the major players in the market include Novartis, Pfizer, Merck, and GlaxoSmithKline. Other companies in the market include Allergan, Galderma, and Sun Pharmaceuticals. Show Less Read more